# **Elabscience Biotechnology Co., Ltd.**



A Reliable Research Partner in Life Science and Medicine

# PD-L1 Monoclonal Antibody(Detector)

catalog number: AN001390P

Note: Centrifuge before opening to ensure complete recovery of vial contents.

<b>D</b>	•	4.0
I IAC	CPH	otion
DCS.		

**Reactivity** Human

Immunogen Recombinant Human PD-L1 L1 protein expressed by Mammalian

Host Mouse
Isotype Mouse IgG2a

Clone 5A7

**Purification** Protein A/G Purification


Conjugation Unconjugated

**Buffer** Phosphate buffered solution, pH 7.2, containing 0.05% proclin 300.

### Applications Recommended Dilution

**ELISA Detector** 0.1-0.4 μg/mL

#### Data



Sandwich ELISA-Recombinant Human PD-L1 L1 protein standard curve.Background subtracted standard curve using PD-L1 antibody(AN001380P)(Capture),PD-L1

antibody(AN001390P)(Detector) in sandwich ELISA.The reference range value for Recombinant Human PD-L1 L1

protein is 0.16-10 ng/mL.

## **Preparation & Storage**

Storage Storage Store at 4°C valid for 12 months or -20°C valid for long term storage, avoid freeze /

thaw cycles.

**Shipping** The product is shipped with ice pack, upon receipt, store it immediately at the

temperature recommended.

#### Background

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (Il10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTIs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.

#### For Research Use Only

Tel: 400-999-2100 Web: www.elabscience.cn Email:techsupport@elabscience.cn